Significant increase. It has been announced that in the early phase 2 clinical trial of a therapeutic drug targeting pediatric patients (5-14 years old) with cartilage imperfection syndrome, a remarkable effect (increase in growth rate) was confirmed in the low-dose subcutaneous administration group. Out of the 6 participants who completed the trial, 5 have transitioned to a long-term low-dose administration trial, continuing to evaluate the effectiveness and safety of the investigational drug. In addition, the high-dose subcutaneous administration trial has completed registration for 7 participants, with administration started in 4 participants, and the results are expected to be revealed in September next year.